News | June 23, 2021
Sun Pharma settles patent litigation for Revlimid
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
Subscribe To Our Newsletter & Stay Updated
